Table 4 The clinical and laboratory characteristics in the 106 patients grouped by HRSV subtype

Clinical characteristics

 Sex^a

P = 0.330

  Male No. (%)

34(45.9)

40(54.1)

  Female No. (%)

18(56.3)

14(43.7)

 Age, months, median (IQR)^b

5.23(1.1–41)

5.17(1.07–21)

P = 0.700

  < 6 ^b

2.77(1.1–5.87)

2.45(1.07–5.67)

P = 0.965

  6–12 ^b

10.87(6.63–11.1)

8.53(6.3–12)

P = 0.503

  12.1–36^c

20(12.47–35)

15.5(12.07–21)

P = 0.051

 Clinical data

  Fever, No. (%) T ≥ 37.5°C^a

20(38.5)

13(24.1)

P = 0.110

  Fever, days, median (IQR)^b

2(0–11)

0(0–8)

P = 0.056

  Cough, No. (%)^a

50(96.2)

54(100)

P = 0.238

  Wheezing, No. (%)^a

34(65.4)

34(63.0)

P = 0.795

  Rales, No. (%)^a

32(61.5)

31(57.4)

P = 0.665

  Respiratory rate, breaths/minute, No. (%)^a

35(67.3)

33(61.1)

P = 0.506

  Heart rate/minute, No. (%)^a

37(71.2)

42(77.8)

P = 0.434

  SpO₂, No. (%)^a

15(28.8)

17/50(34)

P = 0.575

 Final diagnosis

  Bronchopneumonia, No. (%)^a

44(84.6)

46(85.1)

P = 0.935

  Pneumonia, No. (%)^a

7(13.5)

7(13.0)

P = 0.940

  Others, No. (%)^a

1(1.9)

1(1.9)

P = 1.000

  Hospitalization duration, days, (median, IQR)^b

6(3–12)

6.5(1–15)

P = 0.478

Laboratory results

 Hematological analysis

 WBC, × 10⁹/L, median (IQR) ^b

8.4(3–22.8)

8.83(2.25–17.74)

P = 0.378

 Lymphocyte%, median (IQR) ^b

56.5(11.8–80.3)

59.9(9.6–85.5)

P = 0.303

 Neutrophils%, median (IQR) ^b

34.7(9.9–80.5)

29.65(11.1–84.3)

P = 0.310

 Monocyte%, median (IQR)^c

7.25(2.2–15.4)

8.3(0.7–18.2)

P = 0.497

 Acidophil%, median (IQR)^b

0.65(0.0–12.3)

0.8(0.0–10.4)

P = 0.487

 Basophil%, median (IQR)^b

0.3(0.0–1.2)

0.3(0.0–0.7)

P = 0.993

 PLT, × 10⁹/L, median (IQR) ^b

372.5(27.0–803.0)

372.0(166.0–753.0)

P = 0.507

 Hemoglobin, median (IQR) ^b

111.5(90.0–130.0)

117.0(78.0–149.0)

P = 0.108

 CRP, mg/mL, median (IQR)^b

5(0.5–57)

3(0.5–30)

P = 0.007

 Male, median (IQR)^b

5(0.5–42)

3(0.5–30)

P = 0.008

 Female, median (IQR)^b

5(0.5–57)

4(0.5–19)

P = 0.529

Cytokines data

 IL2, No. (%)^a

0/36(0)

1/34(2.9)

P = 0.486

 IL4, No. (%)^a

25/36(69.4)

26/34(76.5)

P = 0.509

 IL6, No. (%)^a

10/36(27.8)

5/34(14.7)

P = 0.183

 IL10, No. (%)^a

31/36(86.1)

22/34(64.7)

P = 0.037

 Male, No. (%)^a

16/21(76.2)

17/24(70.8)

P = 0.685

 Female, No. (%)^a

15/15(100)

5/10(50)

P = 0.005

 TNF, No. (%)^a

0/36(0)

0/34(0)

–

 INF-ɣ, No. (%)^a

4/36(11.1)

3/34(8.8)

P = 1.000

T-cell subsets data

 CD20, below normal range, No. (%)^a

16/32(50)

12/33(36.4)

P = 0.267

 Above normal range, No. (%)^a

8/32(25)

13/33(39.4)

P = 0.215

 CD3, below normal range, No. (%)^a

9/34(26.5)

14/39(35.9)

P = 0.387

 Above normal range, No. (%)^a

13/34(38.2)

14/39(35.9)

P = 0.836

 CD4, below normal range, No. (%)^a

6/34(17.6)

12/39(30.8)

P = 0.194

 Male, No. (%)^a

6/23(26.1)

7/29(24.1)

P = 0.872

 Female, No. (%)^a

0/11(0)

5/10(50)

P = 0.012

 Above normal range, No. (%)^a

20/34(58.8)

21/39(53.8)

P = 0.669

 CD8, below normal range, No. (%)^a

12/34(35.3)

13/39(33.3)

P = 0.860

 Above normal range, No. (%)^a

7/34(20.6)

10/39(25.6)

P = 0.610

 CD3 − CD16 + CD56 + , below normal range, No. (%)^a

20/31(64.5)

21/32(65.6)

P = 0.926

 Above normal range, No. (%)^a

0/31(0)

1/32(3.1)

P = 1.000

 CD4/CD8, below normal range, No. (%)^a

2/34(5.9)

10/39(25.6)

P = 0.029

 Male, No. (%)^a

2/23(26.1)

6/29(24.1)

P = 0.278

 Female, No. (%)^a

0/11(0)

4/10(40)

P = 0.035

 Above normal range, No. (%)^a

16/34(47.1)

15/39(38.5)

P = 0.459

 PCT, No. (%)^a

7/43(16.3)

1/42(2.4)

P = 0.058

 Male, No. (%)^a

3/24(12.5)

0/31(0)

P = 0.077

 Female, No. (%)^a

4/19(21.1)

1/11(9.1)

P = 0.626

Biochemical analysis

 AST, No. (%)^a

14(26.9)

11(20.4)

P = 0.427

 ALT, No. (%)^a

6(11.5)

6(11.1)

P = 0.945

 CK, No. (%)^a

5(9.6)

3(5.6)

P = 0.484

 CK-MB, No. (%)^a

32(61.5)

33(61.1)

P = 0.964

 LDH, No. (%)^a

25(48.1)

20(37.0)

P = 0.250